申请人:Procept, Inc.
公开号:US06075050A1
公开(公告)日:2000-06-13
This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.
本发明涉及发现醛和芳香磺酸及其部分的缩聚聚合物,例如甲醛萘磺酸缩聚聚合物,可以通过CD4/gp120结合实验表明,消除HIV gp120与CD4的结合。除了gp120结合抑制外,这些化合物还被证明可以抑制HIV引起的细胞融合和CD+细胞的感染。这种化合物的使用被证明是非细胞毒性的,并且不会抑制抗原诱导的T淋巴细胞增殖。基于这些发现,这些化合物可以用作治疗获得性免疫缺陷综合症(AIDS),以及AIDS相关复合症(ARC),AIDS相关痴呆和非症状性HIV感染的治疗剂。这些化合物还可以用于治疗血液制剂。